Cardinal Health Is Up 46%-But Fair-Value Bears Still See 28% Too Much

Cardinal Health heads into earnings with valuation front and center

Cardinal Health has built a strong recent track record, but the valuation debate is now the main story. The company has posted a positive one-year share price return after a strong multiyear run, while another model says it is trading about 27.84% above Peter Lynch fair value. Investors are left with two contrasting reads: one valuation framework points to modest upside built on future growth and profitability, while another suggests the stock may already be pricing in a lot of optimism.

August 11 is the near-term catalyst

The key date is August 11, 2026, when earnings are due. In the run-up to the report, shares gained 1.38%, according to the source material. That helps explain the split opinion: bulls see a steady compounder the market continues to reward, while bears see a stock where expectations can move faster than results, especially after a recent 30-day pullback.

Why the valuation split matters

The disagreement is unusually clear-cut. One widely followed model puts fair value at $250.53, while the Peter Lynch-based calculation sits at $165.98. That gap captures the core debate: whether investors will keep paying a premium for Cardinal Health's consistency, or start demanding a lower multiple if sentiment weakens.

My view is that this is still a positioning trade into earnings, not a no-brainer setup. The stock looks attractive only if you have confidence in the longer compounding story and are willing to accept the risk of a sharp pre-earnings move. If not, waiting for the print may be the cleaner approach.